French drug major Sanofi reported Friday higher profit and net sales in its fourth quarter, mainly benefited by strong sales growth of Dupixent, despite weakness in Vaccines and General Medicines. Specialty Care advanced to the largest business unit by sales.
Looking ahead for fiscal 2022, Sanofi expects business earnings per share to grow low double-digit at constant exchange rates from prior year's business earnings per share of 6.56 euros.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com